Commitments and Contingencies (Details Narrative)
|
|
1 Months Ended |
3 Months Ended |
|
Oct. 31, 2017 |
Nov. 30, 2019
USD ($)
|
Nov. 30, 2017
USD ($)
|
Nov. 30, 2016
USD ($)
ft²
|
Mar. 31, 2020
USD ($)
|
Dec. 31, 2019 |
| Monthly lease payments |
|
|
|
|
$ 56,429
|
|
| Alachua Facility [Member] |
|
|
|
|
|
|
| Period of lease |
|
|
|
|
|
5 years
|
| Amended Lease Agreement [Member] | Minimum [Member] |
|
|
|
|
|
|
| Monthly lease payments |
|
|
|
|
$ 12,870
|
|
| Tampa Facility [Member] |
|
|
|
|
|
|
| Period of lease |
|
36 years
|
|
36 months
|
|
|
| Area of office space leased | ft² |
|
|
|
2,207
|
|
|
| Lease expiry date |
|
|
|
Feb. 29, 2020
|
|
|
| Tampa Facility [Member] | Minimum [Member] |
|
|
|
|
|
|
| Monthly lease payments |
|
$ 4,524
|
|
$ 4,138
|
|
|
| Tampa Facility [Member] | Maximum [Member] |
|
|
|
|
|
|
| Monthly lease payments |
|
$ 4,800
|
|
$ 4,392
|
|
|
| Lantibiotic Exclusive Channel Collaboration [Member] |
|
|
|
|
|
|
| Royalty rate percenatge description |
|
|
The Lantibiotic ECC was amended to: (i) consolidate the development milestone payments into one payment of $25,000,000, being due six months after receiving FDA approval of a New Drug Application, (ii) reduce the sublicense revenue percentage we would have had to pay from 50% to 25% of sublicensing revenue, (iii) reduce the royalty rate from 25% of Product Profit to 10% of Net Sales, (iv) revise the form of milestone payments from being share based or cash at the Company's election to only cash, and (v) commit that Diligent Efforts (as defined in the Lantibiotic ECC) in pursuing the Lantibiotic Program would be deemed satisfied in 2018 provided that at least $1,200,000 was budgeted for the advancement of the Lantibiotic Program.
|
|
|
|
| Royalty payment of sublicenses percentage |
|
|
25.00%
|
|
|
|
| Amount required to expended for advancement of lantibiotic program |
|
|
$ 1,200,000
|
|
|
|
| Lantibiotic Exclusive Channel Collaboration [Member] | Net Sales [Member] | Amendment [Member] |
|
|
|
|
|
|
| Royalty payment percentage |
|
|
10.00%
|
|
|
|
| Lantibiotic Exclusive Channel Collaboration [Member] | Cost Of Revenue [Member] |
|
|
|
|
|
|
| Royalty payment percentage |
|
|
25.00%
|
|
|
|
| Lantibiotic Exclusive Channel Collaboration [Member] | Product Profit [Member] |
|
|
|
|
|
|
| Reduction in royalty rate percentage |
|
|
25.00%
|
|
|
|
| Lantibiotic Exclusive Channel Collaboration [Member] | Net Sales [Member] |
|
|
|
|
|
|
| Reduction in royalty rate percentage |
|
|
10.00%
|
|
|
|
| Lantibiotic Exclusive Channel Collaboration [Member] | New Drug Application [Member] |
|
|
|
|
|
|
| Milestone payment under licensing agreement |
|
|
$ 25,000,000
|
|
|
|
| Milestone measurement period |
|
|
6 months
|
|
|
|
| Lantibiotic Exclusive Channel Collaboration [Member] | Regulatory Approval Milestone Event [Member] |
|
|
|
|
|
|
| Milestone payment under licensing agreement |
|
|
$ 25,000,000
|
|
|
|
| Milestone measurement period |
|
|
6 months
|
|
|
|
| Lantibiotic Exclusive Channel Collaboration [Member] | New Indication Milestone Event [Member] |
|
|
|
|
|
|
| Milestone payment under licensing agreement |
|
|
$ 5,000,000
|
|
|
|
| Milestone measurement period |
|
|
6 months
|
|
|
|
| Lantibiotic Exclusive Channel Collaboration [Member] | New Product Milestone Event [Member] |
|
|
|
|
|
|
| Milestone payment under licensing agreement |
|
|
$ 5,000,000
|
|
|
|
| Milestone measurement period |
|
|
6 months
|
|
|
|
| Oral Mucositis Exclusive Channel Collaboration [Member] |
|
|
|
|
|
|
| Milestone payment under licensing agreement |
|
|
$ 27,500,000
|
|
|
|
| Milestone measurement period |
|
|
6 months
|
|
|
|
| Royalty rate percenatge description |
|
|
The Company amended the Oral Mucositis ECC to: (i) consolidate the development milestone payments into one payment of $27,500,000 being due within six months after receiving FDA approval of a New Product Application; (ii) reduce the sublicense revenue percentage from 50% to 25% of sublicensing revenue; and (iii) revise the field in which the Company has exclusive rights to its Oral Mucositis product candidate for the treatment of Oral Mucositis to clarify that the Company has an exclusive for the treatment of Oral Mucositis in humans regardless of etiology.
|
|
|
|
| Royalty payment of sublicenses percentage |
50.00%
|
|
25.00%
|
|
|
|
| Maturity of interest description |
|
|
|
|
The Oral Mucositis ECC provides that in the event (i) Oragenics is required to make a milestone payment in cash as an issuance of shares would cause Precigen ActoBio to consolidate the Company's financial statements with Precigen ActoBio's financial statements, and (ii) Oragenics reasonably concludes that a cash milestone payment would have an adverse effect on its working capital needs over the next twelve (12) months, then such cash payment shall be in the form of an interest bearing promissory note with a maturity date of less than twelve (12) months and include other conventional market terms that would not be expected to unreasonably have an adverse effect on Oragenics working capital needs over such twelve (12) month period.
|
|
| Oral Mucositis Exclusive Channel Collaboration [Member] | Net Sales [Member] | Precigen ActoBio Inc [Member] |
|
|
|
|
|
|
| Royalty payment percentage |
|
|
12.00%
|
|
|
|
| Oral Mucositis Exclusive Channel Collaboration [Member] | Cost Of Revenue [Member] | Precigen ActoBio Inc [Member] |
|
|
|
|
|
|
| Royalty payment percentage |
|
|
25.00%
|
|
|
|
| Oral Mucositis Exclusive Channel Collaboration [Member] | Regulatory Approval Milestone Event [Member] |
|
|
|
|
|
|
| Milestone payment under licensing agreement |
|
|
$ 27,500,000
|
|
|
|
| Milestone measurement period |
|
|
6 months
|
|
|
|
| Oral Mucositis Exclusive Channel Collaboration [Member] | New Indication Milestone Event [Member] |
|
|
|
|
|
|
| Milestone payment under licensing agreement |
|
|
$ 5,000,000
|
|
|
|
| Milestone measurement period |
|
|
6 months
|
|
|
|
| Oral Mucositis Exclusive Channel Collaboration [Member] | New Product Milestone Event [Member] |
|
|
|
|
|
|
| Milestone payment under licensing agreement |
|
|
$ 5,000,000
|
|
|
|
| Milestone measurement period |
|
|
6 months
|
|
|
|
| Amended Lease Agreement [Member] | Maximum [Member] |
|
|
|
|
|
|
| Monthly lease payments |
|
|
|
|
$ 13,338
|
|